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The identification of exclusive markers to target HIV-reservoir cells will represent a sig-
nificant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte
antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is
dimly expressed in a subpopulation of CD4-positive (CD4+) T lymphocytes from blood, with
high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples
from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral
infection selectively upregulates the expression of CD20 during early infection. In samples
from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in
HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which
reduces the pool of HIV-expressing cells when combined with latency reversal agents. We
provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while
on ART.
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HIV infection represents an incurable disease to date. Thepersistence of the HIV-reservoir that is not susceptible tocurrent antiretroviral therapy (ART) represents one of the
main barriers to cure HIV1,2.
During the last two decades, intense efforts have focused on the
search for new markers to successfully identify latently HIV-
infected cells; cells that contain integrated HIV genetically intact
but able to remain quiescent for prolonged periods in vivo.
Recently, the paradigm that most latent HIV is transcriptionally
inactive has been questioned by a new investigation that showed
that most HIV-infected CD4-positive (CD4+) T cells were able to
successfully initiate HIV transcription3. During ART, reservoir
cells expressing HIV RNA are ~10 times more frequent than the
proportion of cells containing replication-competent HIV and are
found in diverse populations of infected cells, including physio-
logically activated cells that produce viral particles upon cell
stimulation4,5. HIV-infected cells might also become pharmaco-
logically activated to produce HIV transcripts by latency reversal
agents (LRAs), which are compounds that are currently being
assessed in clinical trials for their ability to reactivate HIV from
its dormant state. LRAs have been shown to be effective in
inducing HIV transcription, but importantly, viral-reactivated
cells are not completely cleared by the immune system or killed
by viral cytopathic effects in vivo6–8. Thus, the identification of
novel markers to identify transcriptionally active HIV-infected
cells, including physiologically and/or pharmacologically HIV-
reactivated cells, could considerably advance the development of
novel therapies to target and deplete the HIV-reservoir.
CD20 is a cell membrane receptor preferentially expressed on B
cells. Early reports have also demonstrated the existence of a
proportion of CD3-positive (CD3+) T cells with dim expression
levels of CD20 (between 1 and 5% in blood)9–12. In healthy
individuals, CD20-positive (CD20+) T cells are phenotypically
different than their counterpart CD20-negative (CD20−) T cells;
approximately half of them are CD4+ cells, they are more likely
to express the gamma/delta T-cell receptor, and they express
more CD45RO and fewer CD38 molecules on their surface12. In
patients suffering from rheumatoid arthritis13,14 CD20+ T cells
have been found to have a low proliferative capacity, a high
activation state, and an enhanced susceptibility to apoptosis9. In
patients with multiple sclerosis, in vivo administration of the anti-
CD20 monoclonal antibody Rituximab effectively induces long-
term depletion of T cells expressing CD2011. Moreover, CD20+
T cells have been postulated as early T-cell precursors in the
replenishment of diverse populations of T cells11,12. Therefore,
the intrinsic characteristics of CD20+ T cells and their suscept-
ibility to Rituximab administration in vivo make the CD20
molecule a good candidate to explore in the setting of HIV
reservoirs. Here, we investigate CD20 as a putative marker for
HIV infection and during in vivo viral persistence. We find that
CD20 expression in CD4+ T cells is expanded during untreated
HIV infection, and during ART, CD20dim T cells contain high
levels of HIV transcripts. Importantly, Rituximab induces cell
death and decreases the size of the transcriptionally active HIV-
reservoir when combined with LRAs ex vivo. Thus, we identify
CD20 as a new marker for HIV-infected cells in patients and
provide evidence for the combined use of LRAs and anti-CD20
monoclonal antibody therapy for the depletion of HIV-reservoir
cells after viral reactivation.
Results
A subset of CD4+ T cells expresses CD20 in HIV infection.
First, we aimed to determine the proportion of CD4+ T cells
expressing the CD20 molecule during HIV infection in samples
from 21 ART-suppressed patients (<50 copies/ml of plasma viral
load, VL; median time on suppressive ART 48 months), 20 HIV-
viremic patients (median VL 119,000 copies/ml) and 6 uninfected
control donors. The characteristics of individual patients are
shown in Supplementary Table 1. The population of CD4+ T cells
expressing CD20 was identified according to the fluorescence
minus one (FMO) control for CD20 expression (Fig. 1a). As
shown in Fig. 1a and in agreement with previous studies12, we
found that CD4+ T cells expressed dim levels of the CD20
receptor (CD20dim). Importantly, the inclusion of the CD19
marker to exclude B cells did not alter the frequency of CD20dim
CD4+ T cells (Supplementary Fig. 1a). To define the lymphocyte
lineage of CD20dim CD4+ T cells, we performed fluorescent flow
cytometry imaging (Amnis®) on samples from HIV-infected
patients. When cells were gated based on the expression of CD3,
CD4 and dim levels of CD20, we observed the unequivocal
expression of CD20 uniformly distributed through the plasma
membrane of CD4+ T cells. Lack of expression of CD19 on these
CD20dim cells corroborated that they did not belong to a cano-
nical B-cell phenotype (Fig. 1b). B cells were highly positive
for CD19 and CD20 expression (Fig. 1c). Of note, we also found
CD4+ T cells with high expression of CD20, however, the flow
cytometry imaging analysis showed that they corresponded to cell
aggregates consisting of T-B-cell doublets (Supplementary
Fig. 1b). In addition, conventional quantitative PCR showed the
dim expression of CD20-mRNA in previously isolated CD20dim
CD4+ T cells (Supplementary Fig. 1c). Next, we quantified the
percentage of CD20 in CD4+ T cells of HIV+ patients and
uninfected controls. We observed that viremic HIV+ patients
presented statistically significant higher proportions of CD4+
T cells expressing CD20 compared with uninfected donors
(Fig. 1d). Moreover, CD4+ T cells from HIV+ viremic individuals
had slightly higher expression of CD20 than virologically sup-
pressed HIV+ patients. The antiretroviral treatment normalized
the expression of CD20 since no differences were found between
ART-suppressed patients and uninfected controls (Fig. 1d). When
we compared the activation levels, defined by the expression of
HLA-DR, CD69, CD25 or any combination of these cell markers,
we observed that in HIV+ patients CD20dim CD4+ T cells were
more activated than CD4+ T cells not expressing CD20 (Fig. 1e).
Next, we studied the memory phenotype of these cells in HIV
infection. In terms of the distribution of CD20dim among the
different CD4+ T cell subsets, most of the CD20dim cells had a
central memory (TCM) phenotype, followed by the effector
memory (TEM), transitional memory (TTM), and naive (TNA)
phenotypes. CD20dim cells were less distributed among memory
stem cells (TSCM) and terminally differentiated (TTD) cells
(Fig. 1f). Thus, all the memory subsets accounted for almost
80% of the total expression of CD20dim CD4+ T cells. Simulta-
neously, we observed that memory subsets, including CD4+ TCM,
CD4+ TEM, and CD4+ TTM cells, contained significantly higher
percentages of CD20dim-expressing cells, as compared with the
less differentiated CD4+ TNA and CD4+ TSCM, or with the CD4+
TTD cells (Supplementary Fig. 2a). In this regard, small differ-
ences in CD4+ T cell subsets were observed between
ART-suppressed individuals, HIV-viremic individuals, and
uninfected controls (Supplementary Fig. 2b). When we analyzed
all CD4+ T memory cells together, defined by the expression of
CD45RO, we found the same trend observed in the total CD4+ T-
cell population (shown in Fig. 1f), suggesting that these differ-
ences are mainly supported by the memory pool (Supplementary
Fig. 2c). We also studied if CD20dim CD4+ T cells expressed
cell markers characteristics of follicular T helper (TFH) cells,
defined by the expression of PD1 and CXCR5. We observed that
CD20dim cells expressed significantly more double positive
CXCR5+ and PD1+ than CD20− CD4+ T cells (Supplementary
Fig. 1d).
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Finally, we evaluated the relationship between the expression of
CD20 in T cells and markers of HIV progression. A significant
inverse correlation was observed between the percentage of
CD20dim CD4+ T cells and the number of months that patients
were under suppressive treatment (VL < 50 copies/ml), and with
their CD4+ T-cell count (Fig. 1g). A tendency toward a positive
correlation was also observed with the plasma viral load (Fig. 1g).
In summary, HIV+ individuals had higher expression of CD20 on
CD4+ T cells compared with uninfected controls that inversely
correlated with CD4+ T cell counts and time on suppressive ART.
Moreover, the CD20 marker was associated with activated cells
and mainly expressed and distributed in memory CD4+ T-cell
subsets.
CD20dim CD4+ T cells are enriched in intracellular HIV RNA.
Since CD4+ T cells expressing the marker CD20 seem to be more
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activated than the general population of CD4+ T cells, and cell
activation has been related to higher levels of HIV-1 infection and
transcription, we sought to investigate if CD20dim CD4+ T cells
from HIV+ patients might also contain more transcriptionally
active HIV. In general, no correlation was found between the
expression of CD20 in CD4+ T cells and viral nucleic acids
during ART (Supplementary Fig. 2d). Using the novel RNA
FISH-flow assay4, we measured the frequency of CD20dim CD4+
T cells that were co-expressing HIV RNA. We included samples
from 12 ART-suppressed patients (median time on suppressive
ART 23 months), 11 viremic patients (median VL 74,500 copies/ml)
and 4 uninfected controls. The characteristics of the included
patients are shown in Supplementary Table 1. The gating strategy
used to identify CD20dim CD4+ T cells and HIV RNA expression
is shown in Fig. 2a. Both cohorts of HIV-infected patients, vire-
mic and ART-suppressed patients, presented a significantly
higher proportion of CD20dim CD4+ T expressing viral tran-
scripts compared with their counterpart CD20− CD4+ T cells
(Fig. 2b). These infected CD20dim CD4+ T cells contributed to a
median of 18.55% and 25.0% to the total pool of HIV-expressing
cells in ART-suppressed and viremic patients, respectively
(Fig. 2c). Overall, we observed that CD20dim CD4+ T are enri-
ched in HIV RNA and contribute significantly to the total pool of
HIV-expressing cells.
Proviral HIV DNA levels of CD20dim CD4+ T cells. We next
asked if the increased viral transcription observed within the
CD20dim CD4+ T population was associated with enrichment in
viral DNA. We used fluorescence activated cell sorting to isolate
total CD4+ T cells, activated CD4+ T cells (CD20−), resting CD4+
T cells (CD20−), activated CD20dim CD4+ T cells, and resting
CD20dim CD4+ T cells from nine HIV-infected ART-suppressed
individuals (median time on suppressive ART of 156 months)
(Supplementary Table 1). Resting CD20dim CD4+ T cells had
significantly higher levels of HIV DNA compared with the total
CD4+ T cells (Fig. 3a, left panel). This enrichment represented a
2.1-fold change in the amount of HIV DNA per million cells
between both subsets (Fig. 3a, right panel). Moreover, we calcu-
lated the global contribution of these subsets to the total pool of
HIV-infected cells, and we found that resting CD20dim con-
tributed to a median of 13.26% compared with 25.44% and
57.79% of activated CD4+ T cells and resting CD4+ T cells,
respectively (Fig. 3b).
CD20+ T cells are infected in human lymph nodes. We next
visualized and quantified the CD20 receptor in anatomically
intact lymph node tissue preparations from two ART-suppressed
patients and four viremic HIV-infected patients (Supplementary
Table 1). First, we focused on the quantification of T cells co-
expressing the marker CD20. We detected CD20+ T cells in both
the extrafollicular zone and within the B-cell follicle in all samples
analyzed. Representative micrographs are shown in Fig. 4a. In the
sample from one HIV-viremic patient (#82), we observed sig-
nificantly higher absolute number of CD20+ T cells within the B-
cell follicle compared with the extrafollicular region, while the
two ART-suppressed patients had lower quantities of CD20+
T cells in B-cell follicles compared with the viremic patients
(Fig. 4b, upper panel). Also, we quantified the percentage of
follicular CD3+ cells that co-expressed CD20. We found that, in
general, the median percentage of CD3+ cells positive for CD20
expression ranged from 2 to 4% in individual patients (Fig. 4b,
lower panel). Next, we investigated whether HIV-infected cells
were also expressing CD20 in lymph node tissue specimens from
three viremic and one ART-suppressed HIV-infected patients.
Since productively HIV-infected cells have been previously
identified as being CD45RO-positive memory CD4+ T cells15, we
did not perform phenotypic identification of such cells. Instead,
we directly performed immunostaining of the viral protein p24
and the CD20 antigen. P24 showed the typical two-staining
pattern observed in the B-cell follicles16; a network-like staining
probably corresponding to virions captured by follicular dendritic
cells (FDCs), and cells with densely spherical signal indicating
productively HIV-infected cells. Notably, within the B-cell folli-
cles of all patients, we observed productively HIV-infected cells
co-expressing the CD20 molecule (Fig. 4c), but cell quantification
was difficult due to the high density of B cells expressing CD20.
To finally demonstrate the expression of CD20 in productively
HIV-infected cells, we used the in situ hybridization ultrasensitive
RNA detection assay (eBiosciences) to visualize HIV RNA and
CD20 RNA in a lymph node section of one HIV+ viremic patient.
In this particular patient, productively HIV-infected cells were
often associated with the expression of CD20, inside and outside
of the B-cell follicle (Fig. 4d). Overall, we confirm the existence of
HIV-infected cells expressing CD20 in lymph nodes from ART-
suppressed and viremic HIV-infected patients.
HIV upregulates CD20 in T cells during early viral infection.
To investigate the role of HIV-1 replication in the expression of
Fig. 1 CD20dim CD4+ T cells involve memory phenotypes with more activation than CD20− cells. PBMC from uninfected donors, ART-suppressed patients
and viremic patients were stained with CD20, activation markers (HLA-DR, CD69, CD25), and T-cell differentiation markers (CCR7, CD45RO, CD27,
CD95). a Gating strategy used to identify CD20dim CD4+ T cells. Previous sequential gates are represented in Supplementary Fig. 9. Viable CD4+ T cells
(identified by CD3 and CD4 expression) were first selected for the analysis of CD20 expression, defined by its Fluorescence Minus One (FMO) control. T-
cell memory subsets were selected as follows: CD4+ TNA (CCR7+, CD45RO−, CD27+, CD95−), CD4+ TSCM (CCR7+, CD45RO−, CD27+, CD95+); CD4+
TCM (CCR7+, CD45RO+), CD4+ TTM (CCR7−, CD45RO+, CD27+); CD4+ TEM (CCR7−, CD45RO+, CD27−), CD4+ TTD (CCR7−, CD45RO−). b, c
Representative bright-field and pseudo-color fluorescence images of CD20dim CD4+ T cells (b) and B cells (c) from two ART-suppressed patients (#9 and
#22) using the Amnis imaging flow cytometer technology. Scale bar 10 µm. d Percentage of CD20dim expression within CD4+ T cells in uninfected controls
and the two patient cohorts. Mann–Whitney comparison was used to compare n= 6 uninfected controls, n= 21 ART-suppressed patients, n= 20 viremic
patients. e Expression of the activation markers CD25, CD69 or HLA-DR in CD20dim and CD20− CD4+ T cells in different cohorts of HIV+ patients.
Comparisons were performed using the two-tailed Wilcoxon test (n= 21 ART-suppressed patients and n= 20 viremic patients). f Distribution of CD20dim
in CD4+ T-cell subsets in ART-suppressed (orange) and viremic (red) HIV-infected patients. NA, naive; SCM, memory stem cell; CM, central memory;
TM, transitional memory; TD, terminal differentiated. ANOVA and Dunn’s multiple comparison test were performed, n= 10 ART-suppressed and n= 9
viremic patients. Median values and min and max ranks are represented in panels d–f. g Correlation of CD20dim CD4+ T cells with time on suppressive
ART (left), CD4+ T-cell counts (middle) and plasma viral load (right) are shown. ART-suppressed patients in orange and viremic patients in red.
Spearman’s nonparametric correlation coefficients and associated P values are shown. Panels (d) and (e) included patients #2–10, 15–26, 60–65, 67–74,
and 76–81. Panel (f) patients #1–10, 60–65, and 67–69. Panel (g) patients #2–10, 15–26, 60–65, 67–74, and 76–81. Data underlying this Figure are
provided as Source Data file
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CD20, we performed ex vivo infection experiments. Unstimulated
PBMCs from three uninfected donors were infected with the viral
strain NL4.3 for 5 days. The gating strategy for productively HIV-
infected cells, identified as HIV RNA-positive (HIV RNA+) and
p24-positive (p24+) T cells, and expression of CD20 are shown in
Fig. 5a. Ex vivo infection was successfully detected using this
novel assay; we obtained increasing percentages of HIV infection
over time (Fig. 5b left). Interestingly, when we focused on
CD20dim T cells, we observed that this subpopulation supported
HIV infection more efficiently than CD20− T cells (Fig. 5b right).
Moreover, the contribution of infected CD20dim T cells to the
total pool of HIV-infected cells significantly increased over time,
reaching 30% at day 5 post-infection (Fig. 5c left). Of note, we
also observed that CD20 expression was increased in the general
population of T cells after infection (Fig. 5c right), indicating that
upregulation of CD20 in infected cells impacted the overall
expression of CD20 in the cell culture. Notably, a significant
positive correlation was found between the percentage of pro-
ductive HIV-infected cells and the percentage of CD20+ infected
cells (Fig. 5d left), or with the mean fluorescence intensity of
CD20 expression of the infected fraction (Fig. 5d right), sug-
gesting a selective upregulation of CD20 in HIV-infected cells. In
addition, in order to show the unequivocal upregulation of CD20
after HIV infection, we performed cell sorting of the CD4+ CD20−
population before cell infection. Again, a clear induction of CD20
expression after 3 days of cell infection was observed (Supple-
mentary Fig. 3a, b). This result was confirmed by quantification of
CD20-mRNA before and after cell infection using qPCR (Supple-
mentary Fig. 3c). Since we have recently described that CD32 is
also upregulated in HIV-infected cells17, we next investigated the
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Fig. 2 CD20dim CD4+ T cells are enriched in HIV-1 RNA. Unstimulated PBMCs were subjected to the RNA FISH-flow protocol to detect HIV RNA
expression in CD20dim CD4+ T cells. a Gating strategy used to determine the HIV RNA expression on CD20− and CD20dim CD4+ T cells and expression
of CD20 in HIV RNA+ cells. Previous sequential gates are represented in Supplementary Fig. 9. b Frequency comparison of HIV RNA+ cells in CD20dim
CD4+ T cells and CD20− CD4+ T cells of ART-suppressed and viremic patients. Wilcoxon test was used. c Mean distribution of HIV RNA+ cells in the
CD20+ and CD20− phenotypes. Median values and min and max ranks are represented in panels (b) and (c). In all panels, n= 12 ART-suppressed and
n= 11 viremic patients are shown. Data from patients #15–26, 60, 63, and 73–81 are included. Data underlying this Figure are provided as Source Data file
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relationship between these two markers. We observed that in HIV-
infected cells, CD20 was upregulated to a greater extent than CD32
(Supplementary Fig. 4). Finally, we observed that CD20dim HIV-
infected cells expressed more frequently HLA-DR than CD20−
HIV-infected cells (ANOVA p= 0.001), and also the immune
checkpoint marker PD-1 (ANOVA p= 0.01) (Fig. 5e). To ascertain
the dynamics of CD20 expression in HIV-infected cells, we took
advantage of the CD4 downregulation induced by HIV in highly
productive HIV-infected cells. During early infection, defined by
infected cells expressing CD4, levels of CD20 were notably higher
than during late infection, as defined by cells with marked down-
regulation of the CD4 receptor (Fig. 5f). The opposite trend was
observed for the activation marker HLA-DR (Supplementary
Fig. 5a). These results suggest that this early upregulation of CD20
upon HIV infection might be a virus-specific effect, since the
general activation of T cells with anti-CD3 and CD28 antibodies
only increased the expression of CD20 over time (96 h) slightly. In
contrast, CD69 and HLA-DR were strongly upregulated after CD3/
CD28 activation (Supplementary Fig. 5b).
Rituximab targets HIV-infected CD20dim CD4+ T cells
in vitro. Rituximab is a chimeric monoclonal antibody directed
against the B-cell-specific antigen CD20 used to deplete B cells in
certain types of lymphoma18. We tested if Rituximab could also
target and deplete T cells expressing low levels of CD20. PBMCs
from uninfected donors and three ART-suppressed individuals
(median time on suppressive ART of 336 months) (Supplemen-
tary Table 1) were treated with 10 µg/ml of Rituximab for 48 h. As
expected, Rituximab significantly reduced the number of B cells
(Fig. 6a). Moreover, a marked decreased of CD20dim CD4+
T cells in culture was also observed (Fig. 6b). We also studied if
Rituximab induced antibody-dependent cell-mediated cytotoxi-
city (ADCC) of CD20dim CD4+ T cells. To achieve this goal,
Rituximab-treated CD4+ T cells, stained with the eFluor670 dye
as previously shown19, were used as target cells in combination
with Natural killer (NK) effector cells. We found that NK cells
were responsible for inducing a potent ADCC response that
significantly reduced the proportion of CD20dim CD4+ T cells
(Fig. 6c). Gating strategy and the individual data are shown in
Supplementary Fig. 6.
Since we have observed that CD20 was upregulated upon HIV
infection and Rituximab efficiently targeted CD20dim CD4+
T cells, we next asked if Rituximab had any impact on ex vivo
infection cultures of unstimulated PBMCs. Addition of Rituximab
to the cell culture completely abrogated productive HIV infection
of CD20dim CD4+ T cells (Fig. 6d, left panel). It is noteworthy
that the entire population of CD20dim CD4+ T cells was not
depleted by Rituximab (as observed in Fig. 6b); however, cells that
were efficiently eliminated were those supporting productive HIV
infection. Moreover, Rituximab impacted the total pool of
infected CD4+ T cells, reducing HIV infection by 38.6% at day
3 (Fig. 6d, right panel).
In vivo administration of Rituximab targets HIV-RNA+ cells.
To assess the in vivo effect of Rituximab on the HIV-reservoir, we
took advantage of available samples obtained from three ART-
suppressed patients receiving Rituximab for non-malignant rea-
sons. Patient #52 received Rituximab at 1000 mg/dose on days 0
and 14 due to an IgG4-related systemic disease. Patient #53 only
received one dose of 1000 mg due to fibrillar glomerulonephritis.
Patient #59 received three doses of 375 mg/m2 of Rituximab at
days 0, 7, and 33 due to a mucocutaneous ulcer caused by
Epstein–Bar virus. Consistent with our in vitro data, we observed
that Rituximab efficiently depleted more than 80% of CD20dim
CD4+ T cells in the three patients, and this depletion was con-
tinually sustained throughout the study (Fig. 7a, b). Moreover, we
measured intracellular HIV RNA in isolated CD4+ T cells in
these patients. Although no LRAs were administrated to the
patients, we observed a transient 2.38 fold-decrease of HIV RNA
in one patient (#52), a sustained 2.4-fold reduction of HIV RNA
in the second patient (#53), and no significant changes in patient
#59 (Fig. 7c). The low basal HIV transcription level observed in
the third patient might explain the lack of rituximab effect on
HIV+ cells. As body distribution of different cell subpopulations
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might impact detection of HIV-RNA+ cells in blood, we quan-
tified the proportion of major CD4+ T-cell subsets after Ritux-
imab administration. No consistent changes in cell proportions
were observed (Supplementary Fig. 7).
Rituximab impacts HIV+ cells after viral reactivation. As the
frequency of CD20 expression in CD4+ T cells is relatively low,
and HIV infection upregulates CD20, we wondered if reactivation
of the latent reservoir might also upregulate CD20 in HIV-
infected cells and render cells susceptible to Rituximab. Samples
from ART-suppressed patients were included in these studies
(median time on suppressive ART of 23 months) (Supplementary
Table 1). First, we performed in vitro reactivation assays using
fresh CD4+ T cells from eight ART-suppressed HIV-infected
patients. The LRAs romidepsin, ingenol or the positive control
PMA/ionomycin were added to cells and the expression of HIV
RNA was assessed by the RNA FISH-flow assay (Fig. 8a). The
addition of romidepsin and ingenol significantly increased the
proportion of CD20dim cells expressing viral transcripts, with
higher frequencies observed in CD20dim cells compared with
CD20-negative cells in all conditions (Fig. 8b), and with a con-
comitant increase in the proportion of infected cells expressing
CD20dim in the whole population of CD4+ T cells (Fig. 8c). Under
all conditions tested, cells expressing HIV RNA presented higher
levels of CD20dim compared with uninfected cells. In addition,
ingenol and PMA/ionomycin induced a significant upregulation of
CD20dim in the whole population of infected CD4+ T cells after
viral reactivation. A very low upregulation of CD20 in uninfected
cells and CD8 T cells was also observed for ingenol and PMA/
ionomycin (Fig. 8d).
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Next, we investigated whether Rituximab was able to impact
cells actively transcribing HIV RNA after pharmacological viral
reactivation in 12 ART-suppressed patients. PBMCs from these
patients were incubated for 24 h with Rituximab and romidepsin
or panobinostat, and for an additional 24 h with Rituximab.
Thereafter, CD4+ T cells were isolated and HIV RNA quantified
by conventional qPCR. We observed successful viral reactivation
in 7 out of 12 samples tested (median fold-change reactivation of
3.7). Importantly, the potency to induce viral reactivation by
LRAs was directly associated with the fold-change reduction of
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RNA-expressing cells by Rituximab (Fig. 8e). Moreover, in the
seven samples responding to LRA viral reactivation, Rituximab
induced significant depletion of HIV RNA-expressing cells
compared with cells non-responding to LRAs (Fig. 8f), with a
median reduction of HIV RNA of 64% [18–87]. For samples
responding to LRA treatment, individual patterns of viral RNA
expression in the presence of LRAs with or without Rituximab are
shown in Supplementary Fig. 8. Overall, Rituximab was capable
of targeting and deplete cells expressing HIV RNA after viral
reactivation. However, the ability of Rituximab to impact this
transcriptionally active viral reservoir directly depended on the
ability of LRAs to induce viral transcription.
Discussion
Understanding the mechanisms that contribute to HIV-1 per-
sistence despite ART, and the development of therapeutic stra-
tegies to target persistent virus, represent current priorities in
HIV-1 research20,21. Here we report the existence of a significant
fraction of circulating CD4+ T cells that express CD20, a cell
membrane receptor preferentially expressed on B cells, which
associates with HIV infection and cells enriched for viral RNA in
ART-suppressed patients. Importantly, treatment with Rituximab
eliminates this fraction while impacting on the HIV-viral reser-
voir when combined with LRAs.
Using different methodologies we unequivocally demonstrated
that CD20dim CD4+ T cells are a truly single cell fraction, and
they are not the result of flow cytometry artifacts, as previously
shown for T cells expressing high levels of CD3222. We found that
a small proportion of CD4+ T cells expressed dim levels of CD20,
and this population was significantly expanded by ~2-fold in
viremic patients. These findings, together with the enrichment of
HIV RNA in this subpopulation, the upregulation of CD20 after
in vitro infection, and the normalization of CD20 levels in ART-
suppressed individuals, strongly suggests a direct link between
HIV infection and the expression of CD20. Moreover, the fre-
quency of CD4+ T cells expressing CD20 inversely correlated
with CD4+ T-cell counts and the time on suppressive ART. This
phenomenon has been extensively reported for conventional
activation markers, such as CD38 and HLA-DR23,24. Thus, it is
tempting to speculate that CD20 might behave as a non-
conventional activation marker during HIV infection for CD4+
T cells. We found that in general, ~1% of CD4+ T cells expressed
CD20, and most of those cells had a memory phenotype. These
percentages of expression have been previously reported in
patients with multiple sclerosis and rheumatoid arthritis9,25. In
agreement with our results, Schuh and colleagues studied features
of human CD3+ CD20dim cells during multiple sclerosis and
found that these T cells were enriched in CD45RO+ memory
cells25. We also found that CD4+ T cells expressing the CD20
marker were in general more activated than their CD20− coun-
terparts. Accordingly, increased activation of T cells expressing
CD20 has been widely reported26.
The identification of specific cell subpopulations harboring
HIV is important for the design of novel therapies directed to
Fig. 5 Ex vivo infection upregulates CD20 expression. Unstimulated PBMCs from three uninfected donors were infected with HIV strain NL4.3. Infection
was monitored by simultaneous staining of HIV RNA using the RNA FISH-flow assay and the viral protein p24 at days 3, 4, and 5. a Gating strategy used to
monitor HIV infection and expression of CD20dim. Previous sequential gates are represented in Supplementary Fig. 9. b Percentage of productively HIV-
infected cells in CD3+ T cells (left panel) and in CD20dim or CD20− CD3+ T cells (right panel). c Expression of CD20dim in infected and uninfected CD3+
T cells (left panel) and in the total CD3+ T cell population (right panel). d Correlation between the proportion of infected cells within the CD3+ T cell
population and CD20 expression (left panel) and the mean fluorescence intensity (MFI) of CD20 (right panel). e Percentage of HLA-DR and PD-1 in
infected and uninfected cells expressing or not expressing CD20dim. f Proportion of CD20dim in infected cells expressing the CD4 cell receptor versus
infected cells with marked downregulation of the CD4 receptor. In all panels, the mean and SEM value of three independent experiments is represented. In
panel (d), Spearman’s nonparametric correlation coefficients and associated p values are shown. Data underlying this Figure are provided as Source
Data file
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deplete the latent viral reservoir. We observed that CD20dim CD4+
T cells were not particularly enriched in HIV DNA, compared
with levels reported in other memory subsets27,28. However, we
observed a significantly higher proportion of these cells expres-
sing HIV RNA transcripts with a significant contribution to the
total pool of HIV RNA-expressing cells. This result concur with
HIV-RNA expression by other memory pools4 and with the
higher activation status of CD20dim cells. Other markers for
transcriptionally active HIV-infected cells have been described
recently: CD3217,29,30 and CD3031. A common link between three
markers, CD20, CD30 and CD32, is their relationship with
increased levels of cell activation. However, we found that a
minority of HIV-infected cells co-expressed CD20 and CD32 in
blood. Thus, although CD20 and CD32 were both upregulated in
HIV-infected cells, we speculate that the expression kinetics and/
or its cellular origin might be different. To date, the mechanism
and function of these two markers in transcriptionally active
HIV-infected cells remain unknown and merit further
investigation.
In our in vitro model of HIV infection we showed that HIV
replication increased the expression of CD20. Although only 30%
of HIV-infected cells expressed CD20, a clear association was
observed between infection and proportion of CD20. For instance,
we observed that CD20 upregulation was stronger during the early
events of HIV infection. Importantly, this result might explain the
lack of CD20 expression in all HIV-infected cells analyzed. Based
on these results, we conclude that CD20 expression is specially
upregulated during HIV infection, but also it might slightly
increase upon cell activation. We present several evidences sup-
porting this argument: (i) we demonstrated that stimulation of
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to the RNA FISH-flow assay for the detection of HIV RNA transcripts. a Representative flow gating strategy used for the analysis. Proportions of cells
expressing HIV RNA within CD20dim and CD20-negative CD4+ T cells (b) or cells expressing HIV RNA and CD20dim in CD4+ T cells (c) are shown.
Medians and min–max rank are represented. The median percentages of CD20dim in infected and uninfected CD4+ T cells, and CD8+ T cells after
treatment with different LRAs are shown in (d). Comparisons were performed using the Wilcoxon test. e, f Unfractionated PBMCs from n= 12 ART-
suppressed patients (#18, 19, 21, 23, 41–48) were treated with the latent reversal agents (LRAs) romidepsin or panobinostat for 24 h, and with Rituximab
for 48 h. HIV RNA expression were measured by qPCR. Panel (e) shows the correlation between the fold-change reactivation by the LRA and the fold-
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uninfected donors with anti-CD3 and anti-CD28 antibodies slightly
promotes CD20 expression in uninfected CD4+ T cells (up to 4%)
(Supplementary Fig. 5b); (ii) LRA treatment slightly increases the
expression of CD20 in HIV-negative cells (up to 5%), but the
upregulation is stronger in HIV+ cells (up to 20%) (Fig. 8d); and
(iii) ex vivo HIV infection of FACS-sorted CD4+CD20− negative
cells strongly upregulates CD20 (~30%) (Supplementary Fig. 3).
Thus, it is tempting to speculate that viral proteins, i.e., Nef, which
has been shown to modulate T-cell activation32, may be involved in
this process. More mechanistic studies are needed to finally eluci-
date the real contribution of the virus to CD20 upregulation. In
concordance with this idea, we found higher expression of CD20 in
HIV-infected cells in lymph nodes, a key sanctuary viral reser-
voir33–36. Thus, it is tempting to speculate that the infected cells
expressing CD20 that we observed in lymph nodes are TFH, a
subpopulation of cells found within B-cell follicles with elevated
expression levels of PD-1 and CXCR5, which are highly permissive
to HIV infection and significant contributors to HIV persistence
during treatment37. In agreement with that, we observed higher
proportions of CD20dim CD4+ T cells expressing PD-1 and
CXCR5 in blood compared with cells lacking CD20 expression, and
follicular T cells expressing CD20 in lymph nodes. This may sug-
gest that the origin of this population may be the lymph nodes. If
this hypothesis is fully confirmed in additional studies, targeting
this subpopulation of HIV-infected cells will be fundamental to
impact HIV persistence.
Critically, we found that Rituximab was able to target CD4+
T cells expressing dim levels of CD20 and induced ADCC
mediated by NK cells. A number of studies have also demon-
strated the effects of anti-CD20 therapy on the T-cell
compartment9,38–40. Importantly, using our in vitro HIV infec-
tion method, we observed that HIV-infected cells expressing
CD20 were successfully eliminated by Rituximab. This finding
suggests that Rituximab treatment during HIV infection might
have a positive effect on controlling viral load. In this regard, in
untreated SIV-infected rhesus monkeys, Rituximab administra-
tion prior to and during SIV infection was associated with
decreased viral load. Interestingly, during chronic follow-up
infection, the viral load was undetectable in six out of seven
animals treated with Rituximab41. However, in another study
with African green monkeys, depletion of CD20+ T cells had no
significant impact on viral load42. In humans, a case report
described the impact of Rituximab alone on HIV viremia; HIV
plasma viral load was maintained while on ART and Rituximab
treatment. After therapy discontinuation, however, the HIV-viral
load was significantly increased, most likely due to a loss of
antibody production43.
The use of anti-CD20 therapy to reduce viral reservoirs in B-
cell follicles had been previously considered44; the destruction of
B-cell follicles using anti-CD20 monoclonal antibodies has been
proposed as a novel strategy to expose HIV-1 reservoirs for
elimination. For instance, in a recent study, HIV-infected patients
with lymphoma or Kaposi Sarcoma received multiple doses of
Rituximab, but reductions in cell-associated HIV RNA or HIV
DNA levels were not observed45. Of note, these patients were
treated with a combination of different antineoplastic drugs,
which included Rituximab. In our study, in two patients treated
only with Rituximab for non-malignant reasons we observed
more than twofold reductions in HIV RNA. Note that, in spite of
cellular associated HIV RNA might naturally fluctuate during
time in ART-treated patients, only 5% of patients are likely to
present a random twofold variation in HIV-RNA levels46.
Ongoing viral replication in particular tissues, i.e., lymph nodes,
potentially impacted by Rituximab might help to explain the
reduction in HIV RNA. Patient #53 was under a dual anti-
retroviral therapy, instead of the recommended triple therapy
regimen, which might help to explain the sustained reduction of
HIV RNA observed in this patient.
Furthermore, our ex vivo data indicate that viral reactivation of
latent cell reservoirs increased the levels of cells co-expressing
HIV RNA and CD20, and consequently, the addition of Ritux-
imab induced depletion of viral-reactivated cells. Based on this
data, we speculate that a large in vivo reactivation of the latent
viral reservoir, i.e., using LRAs, may be an indispensable pre-
requisite for Rituximab to significantly impact long-term HIV
persistence in vivo. Although it is important to consider that a
possible complication of current anti-CD20 therapy could be
immunodeficiency and/or immunopathologies, we provide evi-
dence for the combined use of LRAs and anti-CD20 therapies for
the depletion of viral-reactivated cells in patients on ART. The
future development of new anti-CD20 therapies with less toxicity
and specifically directed to CD4+ T cells might help to implement
this new therapeutic approach.
Methods
Ethics statement. PBMCs from HIV-1-infected patients were obtained from the
HIV unit of the Hospital Universitari Vall d’Hebron and from the Clinic Hospital
in Barcelona, Spain. Study protocols were approved by the Comitè d’Ètica d’In-
vestigació Clínica (Institutional Review Board numbers 39–2016, 196–2015, and
476–2018) of the Hospital Universitari Vall d’Hebron and the Hospital Clinic in
Barcelona, Spain. Samples were obtained from adults, all of whom provided written
informed consent, and were prospectively collected and cryopreserved in the
Biobanc (register number C.0003590). All samples received were completely
anonymous and untraceable.
Study samples. Samples from HIV-1-infected patients with CD4+ T-cell counts
higher than 100 cells/mm3 recruited in the HIV unit of the Hospital Universitari
Vall d’Hebron and the Clinic Hospital in Barcelona, Spain, were included in this
study. Information on plasma viral loads, CD4+ T-cell counts, and time on ART
from suppressed patients is summarized in Supplementary Table 1.
Cells and virus. PBMCs were obtained from HIV-infected patients by Ficoll-Paque
density gradient centrifugation and cryopreserved in liquid nitrogen. PBMCs from
uninfected donors were obtained anonymously from the BST (Banc de Sang i
Teixits, Barcelona, Spain) and isolated as described above. PBMCs were cultured in
RPMI medium (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco),
100 µg/ml streptomycin (Fisher Scientific), and 100 U/ml penicillin (Fisher Sci-
entific) (R10 medium).
The plasmid encoding HIV-1 strain NL4.3 (pNL4.3) was obtained through the
NIH AIDS Reagent Program from Malcom Martin. Viral stocks were generated by
transfection of 293T cells (ATCC, CRL-3216) with pNL4.3, and the resulting viral
particles were titrated in TZMbl cells (NIH AIDS Reagent Program) using an
enzyme luminescence assay (britelite plus kit; PerkinElmer) as described
previously47.
Phenotyping of CD4+ T cells. To identify CD4+ T-cell subsets and the expression
of CD20dim cells, PBMCs were stained for cell surface markers in a final volume of
100 µl with CD3 (PE-Cy7, 2 µl, BD 557851), CD4 (AF700, 1.25 µl, BD 557922),
CD20 (BV785, 2.5 µl, Biolegend 302356), HLA-DR (PE, 2.5 µl, Biolegend 63-9956-
41), CD25 (PE, 1 µl, Biolegend 356103), CD69 (PE, 2.5 µl, Biolegend 310905),
CD27 (FITC, 4 µl, BD 555440), CD45RO (BV605, 1.2 µl, Biolegend 304238), CCR7
(BV711, 1 µl, BD 566602 or PE-CF594, 1 µl, BD 150503) and CD95 (PE-Cy5, 10 µl,
BD 559773) antibodies. Different CD4+ T-cell subset phenotypes were identified as
follows: Naive (NA): CD3+, CD4+, CCR7+, CD45RO−, CD27+, CD95−; stem cell
memory (SCM): CD3+, CD4+, CCR7+, CD45RO−, CD27+, CD95+; central
memory (CM): CD3+, CD4+, CCR7+, CD45RO+; transitional memory (TM):
CD3+, CD4+, CCR7−, CD45RO+, CD27+; effector memory (EM): CD3+, CD4+,
CCR7−, CD45RO+, CD27-, and terminal differentiated (TD): CD3+, CD4+,
CCR7−, CD45RO−. To identify CXCR5 and PD-1 expression in CD4+ CD20dim
T cells, PBMCs were surface stained in 100 µl with CD3 (PE-Cy5, 0.6 µl, Biolegend
300410), CD4 (AF700, 1.25 µl, BD 557922), CD20 (BV785, 2.5 µl, Biolegend
302356), CD19 (FITC, 2.5 µl, BD 560994), CXCR5 (PE, 2 µl, Biolegend 356903),
and PD-1 (PE-Cy7, 0.6 µl, BD 561272) antibodies. Cell viability was determined
with a violet viability dye for flow cytometry (LIVE/DEAD Fixable Violet Dead Cell
Stain Kit; Invitrogen L34963). All samples were acquired with a LSRFortessa flow
cytometer (Becton Dickinson), and the results were analyzed with FlowJo
v10 software (Tree Star).
For fluorescent flow cytometry imaging analyses, PBMCs were stained in 100 µl
with CD3 (PE-Cy7, 2 µl, BD 557851), CD4 (APC, 5 µl, ThermoFisher 17-0048-42),
CD20 (FITC, 2 µl, Biolegend 302303), CD19 (PE, 0.6 µl, Biolegend 302207), and
viability dye (LIVE/DEAD Fixable Violet Dead Cell Stain Kit, Invitrogen L34963).
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Cells were acquired with an AMNIS ImageStremX imaging flow cytometer
(Merck), and data was analyzed using IDEAS v6.1 software. Only focused cells were
considered for analysis, gradient RMS value > 40 was established as a threshold for
best focus.
Quantification of HIV DNA and HIV RNA by quantitative PCR. In accordance
with the manufacturer’s instructions, CD4+ T lymphocytes were enriched from
total PBMCs by negative selection (MagniSort Human CD4+ T Cell Enrichment,
eBioscience) when appropiate. CD4+ T cells were subjected to RNA extraction
using the mirVana™ miRNA Isolation Kit following the protocol instructions
(Ambion). Reverse transcription of RNA to cDNA was performed with Super-
ScriptIII Reverse Transcriptase (Invitrogen) with random primers, and cDNA was
quantified by qPCR with the following primers and probe: LTR R: 5′
GTTCGGGCGCCACTGCTAG 3′; LTR F: 5′ TTAAGCCTCAATAAAGCTTGCC
3′ and LTR Probe: 5′ /56-FAM/ CCAGAGTCA/ZEN/CACAACAGACGGGCA/
31ABkFQ/ 3′. Quantification of RNA copies was performed using a standard curve,
and values were normalized to 1 million CD4+ T cells. In addition, CD4+ T cells
were used to quantify total HIV DNA with the same primers and probe detailed
above. CD4+ T cells were immediately lysed with proteinase K-containing lysis
buffer, and HIV DNA was quantified. Contribution of each subset to the total HIV-
reservoir was calculated by considering the frequency of each subset (analyzed by
flow cytometry) within the total CD4 compartment and their relative infection
frequency.
Detection of HIV RNA+ cells by the RNA FISH-flow assay. The RNA FISH-flow
assay was performed according to manufacturer’s instructions (Human Primer-
Flow RNA Assay, eBioscience) with some modifications. After antibody staining
and cell fixation and permeabilization, cells were ready for hybridization with a set
of 50 probes spanning the whole Gag-Pol HIV mRNA sequence (bases 1165 to
4402 of the HXB2 consensus genome). Next, the cells were subjected to amplifi-
cation signal steps, and HIV RNA was detected using Alexa Fluor 647-labeled
probes. As a negative control, non-HIV-infected donors were included in each
experiment; to normalize the data, the percentage of HIV RNA+ cells detected in
donor samples was subtracted to the real values obtained in the HIV-infected
samples. In these experiments, the following antibody panel was used in 100 µl:
CD3 (PE-Cy5, 0.6 µl, BD 300410), CD4 (BV510, 1.25 µl, BD 344633), CD20
(BV785, 2.5 µl, Biolegend 302356), HLA-DR (PE, 2.5 µl, Biolegend 307605), CD25
(PE, 1 µl, Biolegend 356103), and CD69 (PE, 2.5 µl, Biolegend 310905). Cell via-
bility was analyzed with a violet viability dye (Invitrogen, L34963). Samples were
analyzed with the LSRFortessa flow cytometer, and the results analyzed with
FlowJo v10 software.
Fluorescence activated cell sorting of CD4+ T cells. For the sorting experi-
ments, 100 million PBMCs surface stained in 100 µl with the following: CD3
(PerCP, 5 µl, BD 340663), CD4 (AF700, 1.25 µl, BD 557922), CD20 (FITC, 2 µl,
Biolegend 302303), HLA-DR (PE, 2.5 µl, Biolegened 307605), CD69 (PE, 2.5 µl,
Biolegend 310905), and CD25 (PE, 1 µl, Biolegend 356103) or CD3 (PE-Cy7, 2 µl,
BD 557851), CD4 (AF700, 1.25 µl, BD 557922), CD20 (FITC, 2 µl, Biolegend
302303), and CD19 (PE, 0.6 µl, Biolegend 302207) antibodies, and both stained
with a violet viability dye (Invitrogen, L34963). Cells were immediately sorted using
a BD FACSAria Cell Sorter (Flow Cytometry Platform, Institut d’Investigació en
Ciències de la Salut Germans Trias i Pujol, IGTP). For HIV DNA measurements,
different sorted population were defined as follows: total CD4+: CD3+, CD4+,
CD20−; CD4+ activated: CD3+, CD4+, CD20−, HLA-DR+, CD69+, CD25+; CD4+
resting: CD3+, CD4+, CD20−, HLA-DR−, CD69−, CD25−; CD20 activated:
CD3+, CD4+, CD20dim, HLA-DR+, CD69+, CD25+; CD20 resting: CD3+, CD4+,
CD20dim, HLA-DR−, CD69−, CD25−. After cell isolation, cells were subjected to
HIV DNA quantification by qPCR as described above. For CD20-mRNA mea-
surement, the following populations were isolated: CD4+ CD20− T cells: CD3+,
CD4+, CD20−; CD4+ CD20dim T cells: CD3+, CD4+, CD20dim; B cells: CD3−,
CD4−; CD20+, CD19+. Total RNA was extracted and cDNA was generated as
described above. Levels of CD20-mRNA were relatively quantified using the β-actin
reference gene (PerfeCTa® qPCR FastMix II®, ROX, Quantabio) and applying the
2−ΔΔCT method.
Immunohistochemistry of human lymph nodes. For immunodetection of CD20,
CD3, and p24, formalin-fixed and paraffin-embedded (FFPE) sections from human
lymph nodes of HIV-infected patients were dewaxed and placed in decreasing
ethanol concentrations. Heat-induced epitope retrieval was performed by auto-
claving at 120 °C for 15 min in a citrate buffer pH 6 (Abcam). Then, the slides were
permeabilized in 1X Tris-buffered saline (TBS) (Fisher scientific) with 0.1% Triton
X-100 (Sigma-Aldrich) and 1% BSA (Sigma-Aldrich) for 10 min. Subsequently,
blocking was added for 2 h with 1X TBS supplemented with 10% normal donkey
serum (Jackson Immunoresearch) and 1% BSA. The slides were incubated with
primary antibodies overnight at 4 °C: anti-CD20 (goat-polyclonal anti-CD20
antibody, 1/100, Abcam ab194970), anti-CD3 (mouse-monoclonal anti-CD3
antibody, 1/100, Leica Biosystems NCL-L-CD3-565), or anti-p24 (mouse-mono-
clonal anti-p24 antibody, 1/10, Dako-Agilent M0857), diluted in TBS 1 ×−1%
BSA. Next, samples were washed and incubated for 1 h with the appropriate
secondary antibody: Alexa Fluor 546 donkey anti-goat (Invitrogen, 712-586-150)
and Alexa Fluor 647 donkey anti-mouse (Invitrogen, A-31571), counterstained
with DAPI (4′,6-diamidino-2-phenylindole-dilactate, ThermoFisher), and moun-
ted with Fluoromount G (eBioscience).
Detection of RNA in lymph nodes by in situ hybridization. We used the
ultrasensitive ViewRNA ISH Tissue 2-Plex Assay Kit (eBioscience) to detect HIV
RNA and CD20-mRNA in lymph node tissue samples. Briefly, tissue was fixed and
embedded in paraffin. Sections were mounted on Superfrost Plus microscope slides
(Fisher Scientifics). Before the assay was performed, samples were dewaxed in
Xylene and dehydrated with ethanol. Sample pretreatment was performed by
boiling sections in pretreatment solution for 10 min and protease digestion for
20 min at 40 °C. Hybridization was carried out by slide incubation with target
probes for 2 h at 40 °C. Next day, signal amplification was performed by sequential
incubation of Pre-Amplifiers, Amplifiers and label probes. Finally, samples were
counterstained with DAPI.
Confocal microscopy and quantification. Samples were imaged on an Olympus
Spectral Confocal Microscope FV1000 using a ×20 and ×40 phase objective and
sequential mode to separately capture the fluorescence from the different fluor-
ochromes at an image resolution of 800 × 800 pixels. ImageJ software was used to
perform image processing and analysis. For CD20/CD3 colocalization analysis, a
binary mask was generated for each channel, and the “analyze particles” tool was
used to count single and double-stained cells. In all experiments, at least 10 B-cell
follicles were analyzed per patient.
Ex vivo infection of unstimulated PBMCs. PBMCs from uninfected donors were
thawed and incubated overnight in R10 with 40 U/ml interleukin-2 (IL-2). The
next day, PBMCs were incubated for 4 h at 37 °C with 350,000 TCID50 (50% tissue
culture infectious dose) of NL4.3 viral strain. Cells were then thoroughly washed
and cultured in 96-well plates with R10 containing 100 U/ml IL-2 for the next
6 days. To follow HIV RNA expression, on days 3, 4, and 5, at least 5 million cells
were collected and subjected to the RNA FISH-flow assay. Target-specific Alexa
Fluor 647-labeled probes were used to detect HIV-1-RNA; the expression of Gag
p24 viral protein was determined using a p24-PE antibody (Beckman Coulter).
Surface staining was performed in 100 µl with CD4 (BV510, 1.25 µl, Biolegend
344633), CD3 (PE-Cy5, 0.6 µl, Biolegend 300410), CD20 (BV785, 2.5 µl, Biolegend
302356), HLA-DR (Pe-Dazzle 594, 2.5 µl, BioLegend 307653), and PD-1 (BV605,
2.5 µl, BD 563245).
In the experiments with Rituximab treatment during ex vivo infection, at 4 h
after infection cells were cultured with R10 supplemented with 100 U/ml IL-2 and
10 µg/ml Rituximab, or 10 µg/ml control antibody. At day 3, Rituximab (10 µg/ml)
and the control antibody (10 µg/ml) were replaced. Infection was analyzed by p24-
PE intracellular staining at days 3, 4, and 5. Surface staining was performed in
100 µl with CD3 (PE-Cy7, 2.5 µl, BD 557851), CD4 (AF700, 1.25 µl, BD 557922),
CD20 (BV785, 2.5 µl, Biolegend 302356), and CD19 (FITC, 2.5 µl, BD 560994). All
samples were acquired on a LSRFortessa and analyzed with FlowJo v10 software.
Ex vivo infection of CD20− CD4+ T cells. Seventy million PBMCs were used for
cell sorting experiments. Briefly, cells were stained in 100 µl with antibodies
recognizing CD3 (PE-Cy7, 2.5 µl, BD 557851), CD4 (AF700, 1.25 µl, BD 557922),
and CD20 (FITC, 2 µl, Biolegend 302303). A violet dye was used as a viability
marker (Invitrogen, L34963). The population CD20− CD4+ CD3+ was imme-
diately sorted using a BD FACSAria Cell Sorter. Cells were incubated overnight in
R10 supplemented with 100 U/ml of IL-2, and the day after cells were infected
with 350,000 TCID50 of the NL4.3 viral strain by spinoculation (2 h, 1200 g at
37 °C). Cells were thoroughly washed and cultured in 96-well plates with R10
containing 40 U/ml IL-2 for the next 3 days. On days 0 and 3 cells were collected
and subjected to flow cytometry and total RNA extraction. Upregulation of CD20
expression was identified by flow cytometry using the antibodies in 100 µl CD3
(PE-Cy7, 2.5 µl, BD 557851), CD4 (AF700, 1.25 µl, BD 557922), and CD20
(BV785, 2.5 µl, Biolegend 302356). Levels of CD20-mRNA were relatively
quantified using the β-actin reference gene (PerfeCTa® qPCR FastMix II®, ROX,
Quantabio) and applying the 2−ΔΔCT method.
Quantification of cell death after Rituximab treatment. PBMCs from uninfected
donors and ART-suppressed HIV-infected individuals were cultured with R10 in
the presence of 10 µg/ml Rituximab or the control antibody Palivizumab for 48 h.
Subsequently, cells were processed for flow cytometry and stained with violet
viability dye (Invitrogen, L34963), Annexin V (PE, 2 µl in 100 µl, Biolegend
640907), CD3 (PE-Cy7, 2.5 µl in 100 µl, BD 557851), CD4 (AF700, 1.25 µl in 100 µl,
BD 557922), and CD20, for which we used the combination of Rituximab and anti-
human AlexaFluor488 (ThermoFisher, 31531). The analysis was performed using a
LSRFortessa cytometer. Antibody-dependent cell-mediated cytotoxicity (ADCC)
was measured as follows. Target CD4+ T cells were isolated from uninfected donor
PBMCs as described above. CD4+ T cells were stained with the cell proliferation
dye eF670 following manufacturer’s instructions (Labclinics) and then incubated
with 10 µg/ml of Rituximab for 30 min; cells treated with with the control antibody
Palivizumab were used as a negative control. Target cells were plated in U-bottom
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96-well plates (5.000 cells/well, 20 wells per condition). In parallel, NK cells were
isolated from PBMCs from uninfected donors using a commercial kit (MagniSort™
Human NK cell Enrichment Kit, eBiosciences) and plated at 100.000 cells/well
(ratio target:effector of 1:20). After incubation, cells were stained with 10 µg/ml
Rituximab plus anti-human Alexa Fluor 488 and then analyzed using a LSRFor-
tessa cytometer.
Ex vivo viral reactivation of CD4+ T cells. CD4+ T lymphocytes were isolated as
described above and cultured in R10 alone or stimulated with romidepsin (40 nM),
ingenol (100 nM), or PMA/ionomycin (PMA, 81 nM; ionomycin 1 µM) for 22 h in
the presence of raltegravir (1 µM). Then, cells were washed and subjected to the
RNA FISH-flow assay, as described above. For HIV RNA detection, we used target-
specific Alexa Fluor 647-labeled probes. Surface staining was performed in 100 µl
with CD3 (AF700, 1 µl, Biolegend 300423), CD95 (PE-Cy5, 10 µl, BD 559773),
HLA-DR (BV711, 0.6 µl, Biolegend 307644), CD20 (BV785, 2.5 µl, Biolegend
302356), CCR7 (PE-CF594, 1 µl, BD 150503), p24 (PE, 5 µl, Beckman Coulter),
CD45RO (BV605, 1.25 µl, Biolegend 304238), and CD27 (FITC, 4 µl, BD 555440).
Samples were analyzed using a LSRFortessa flow cytometer.
Quantification of HIV RNA after viral reactivation. Total PBMCs from ART-
suppressed patients were incubated for 21 h with R10 containing raltegravir
(1 µM), nevirapine (100 nM), 10 µg/ml Rituximab or the control antibody Palivi-
zumab, and the LRA romidepsin (40 nM) or panobinostat (30 nM). The LRA was
then extensively washed, and cells were cultured for an additional 24 h in R10 with
10 µg/ml Rituximab or the control antibody. Controls consisting of a cell culture
without the LRA and a culture with the control antibody Palivizumab were
included for each sample tested. After incubation, CD4+ T cells were isolated by
negative selection as described above, and intracellular RNA was extracted and
quantified as described above. The fold-change reactivation was calculated by
dividing the quantification of HIV RNA (molecules of HIV RNA per million CD4+
cells) produced in the presence of romidepsin or panobinostat by the levels (or
quantification) of viral RNA without the addition of the LRA. The fold-change
depletion of HIV RNA induced by Rituximab was calculated by dividing the levels
of viral RNA induced by romidepsin or panobinostat by the HIV RNA levels after
LRA and Rituximab incubation.
Cell activation. PBMCs from uninfected donors were cultured in R10 plus
20 U/ml IL-2 with or without the activating antibodies anti-CD3 (1 µg/ml) and
anti-CD28 (2 µg/ml). Expression levels of CD20, CD69, and HLA-DR were ana-
lyzed at 0, 24, 48, 72, and 96 h. At each time point, cells were stained with 100 µl
CD4 (AF700, 1.25 µl, BD 557922), CD3 (PE-Cy7, 2.5 µl, BD 557851), CD20 (FITC,
2 µl, Biolegend 302303), HLA-DR (Pe-Dazzle 594, 2.5 µl, BioLegend 307653),
CD69 (PE, 2.5 µl, Biolegend 310905), and CD14 (APC, 5 µl, BD 561708), and
samples were analyzed using a LSRFortessa flow cytometer.
Statistical analyses. Statistical analyses were performed with Prism software,
version 6.0 (GraphPad). Nonparametric Mann–Whitney U tests, Wilcoxon rank
and ANOVA Dunn’s multiple comparison tests were used as appropriate. For
correlations, Spearman’s correlation coefficient was calculated. A p value < 0.05 was
considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data underlying figures are provided as Source Data files. All other data are available
from the corresponding author upon reasonable requests.
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